U.S. FDA Approves Kite's Tecartus® as the First and Onl

65% of Patients Achieved Overall Complete Remission with Tecartus -- -- High Unmet Need: Fifty Percent of Adult Patients Will Relapse on Currently Available Treatments -- -- Approval Marks Kite’s Fourth Indication for its Cell Therapies and First in Leukemia -- Kite, a Gilead Company today announced the U.S. Food and Drug Administration has granted approval for Tecartus ® for the treatment of adult patients with ...

Related Keywords

Florida , United States , California , Tampa , Santa Monica , United Kingdom , Foster City , America , American , Bijal Shah , Christi Shaw , Mary Lynn Carver , Jacquie Ross , Lee Greenberger , Gilead Sciences , American Society Of Clinical Oncology , Linkedin , Leukemia Lymphoma Society , Drug Administration , Moffitt Cancer Center , Gilead Sciences Inc , Us Authorized Treatment Centers , Exchange Commission , Gilead Company , Gilead Public Affairs , European Union , Gilead Company Nasdaq , Patients Achieved Overall Complete Remission , High Unmet Need , Fifty Percent , Adult Patients Will Relapse , Currently Available Treatments , Approval Marks Kite , Fourth Indication , Cell Therapies , Therapy Designation , Treatment Centers , Cell Therapy , Chief Executive Officer , Chief Scientific Officer , Lymphoma Society , Risk Evaluation , Mitigation Strategy , Important Safety , Clinical Oncology , Annual Meeting , North America , Release Syndrome , Use Machines , Prescribing Information , Private Securities Litigation Reform Act , Quarterly Report , Flynn Carver ,